{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:05:38Z","timestamp":1774965938497,"version":"3.50.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013115","name":"Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013115","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>As SARS-CoV-2 variants continue to spread, breakthrough infections (BTI) provide real-world insights into the durability and heterogeneity of COVID-19 vaccine-induced immunity. This study aimed to characterize the immune response dynamics and reconstruction characteristics after BTI in participants with different vaccination regimens in Zhejiang Province, China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 370 participants were enrolled from a stratified random sample of permanent residents. Participants were either unvaccinated or had received one of the following vaccine regimens: one dose of adenoviral vector vaccine, two or three doses of inactivated vaccine, or, three doses of recombinant protein subunit vaccine. Paired serum samples were collected after vaccination and after BTI. RBD-IgG levels, pseudovirus neutralizing activity, and eight cytokines were systematically quantified. Correlation analyses and post-infection lower-quartile subgroup (T2-LQ) analyses were performed to assess immune heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>All vaccine groups exhibited robust seroconversion, with post\u2212vaccination RBD\u2212IgG positivity exceeding 90% for both inactivated and recombinant vaccines. Following BTI, antibody levels and neutralizing activity increased significantly across all vaccine groups, consistent with the boosting effect of hybrid immunity. Cytokine profiling analyses revealed minimal differences between vaccine groups post-infection, with immune dynamics primarily driven by longitudinal changes. Notably, IL-13 levels declined consistently across all groups, accompanied by modest changes in the overall cytokine profile. Correlation analyses did not identify a stable concordance between antibodies and cytokines. However, variant-specific RBD-IgG measurements were highly correlated at both time points. Additionally, a post-infection lower-quartile subgroup (T2-LQ) was identified. Among BTI participants, baseline WT-specific RBD-IgG levels were comparable between T2-LQ and non-LQ individuals, suggesting that the low-responder phenotype is not simply attributable to pre-infection antibody levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This paired\u2212sample, population\u2212based study suggests that BTI may further enhance humoral responses and be accompanied by changes in inflammatory\/immunoregulatory markers on top of prior vaccine-induced immunity, while reducing some overall immune differences across vaccine platforms. The identification of the T2-LQ subgroup highlights persistent heterogeneity in post-infection immune responses and suggests the potential value of continued immune monitoring in the post-pandemic era.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1801564","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:17:46Z","timestamp":1774963066000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world immune dynamics following COVID-19 vaccination and breakthrough infection: a paired-sample study in Zhejiang Province, China"],"prefix":"10.3389","volume":"17","author":[{"given":"Yuxin","family":"Hu","sequence":"first","affiliation":[{"name":"School of Laboratory Medicine and Bioengineering, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Key Laboratory of Biomarkers and In Vitro Diagnosis Translation of Zhejiang Province, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youhong","family":"Weng","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Bioengineering, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Key Laboratory of Biomarkers and In Vitro Diagnosis Translation of Zhejiang Province, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Department of Clinic Laboratory, The Fifth Affiliated Hospital of Wenzhou Medical University","place":["Lishui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Li","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Bioengineering, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Key Laboratory of Biomarkers and In Vitro Diagnosis Translation of Zhejiang Province, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yihua","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Clinic, Lishui Second People\u2019s Hospital Affiliated to Wenzhou Medical University","place":["Lishui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinren","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Zhejiang Key Lab of Vaccine, Infectious Disease Prevention and Control, Zhejiang Provincial Center for Disease Control and Prevention","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahan","family":"Wu","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Bioengineering, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Key Laboratory of Biomarkers and In Vitro Diagnosis Translation of Zhejiang Province, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rongxian","family":"Liao","sequence":"additional","affiliation":[{"name":"The Third Hospital of Quzhou","place":["Quzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoyao","family":"Gong","sequence":"additional","affiliation":[{"name":"The Third Hospital of Quzhou","place":["Quzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Longyou","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Clinic, Lishui Second People\u2019s Hospital Affiliated to Wenzhou Medical University","place":["Lishui, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dingmei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Epidemiology Department, School of Public Health, Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengke","family":"Han","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Bioengineering, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Key Laboratory of Biomarkers and In Vitro Diagnosis Translation of Zhejiang Province, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[{"name":"The Third Hospital of Quzhou","place":["Quzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoliang","family":"Zheng","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Bioengineering, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Key Laboratory of Biomarkers and In Vitro Diagnosis Translation of Zhejiang Province, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaohong","family":"Lu","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Bioengineering, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Key Laboratory of Biomarkers and In Vitro Diagnosis Translation of Zhejiang Province, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Zhejiang Key Laboratory of High-level Biosafety and Biomedical Transformation, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Engineering Research Center of Novel Vaccine of Zhejiang Province, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingming","family":"Kong","sequence":"additional","affiliation":[{"name":"School of Laboratory Medicine and Bioengineering, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]},{"name":"Key Laboratory of Biomarkers and In Vitro Diagnosis Translation of Zhejiang Province, Zhejiang Provincial People\u2019s Hospital, Affiliated People\u2019s Hospital, Hangzhou Medical College","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enfu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases and Zhejiang Key Lab of Vaccine, Infectious Disease Prevention and Control, Zhejiang Provincial Center for Disease Control and Prevention","place":["Hangzhou, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)30260-9","article-title":"Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study","volume":"395","author":"Wu","year":"2020","journal-title":"Lancet"},{"key":"B2","volume-title":"WHO Coronavirus (COVID-19) dashboard: Cases","year":"2023"},{"key":"B3","unstructured":"Immunization as an essential health service: guiding principles for immunization activities during the COVID-19 pandemic and other times of severe disruption\n          \n          2020"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1050037","article-title":"Complementarity determining regions in SARS-CoV-2 hybrid immunity","volume":"14","author":"Frans","year":"2023","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11030534","article-title":"SARS-CoV-2 breakthrough infections after third doses boost IgG specific salivary and blood antibodies","volume":"11","author":"Badano","year":"2023","journal-title":"Vaccines (Basel)"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100764","article-title":"Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection","volume":"3","author":"Jeong","year":"2022","journal-title":"Cell Rep Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1016\/j.immuni.2022.05.018","article-title":"The magnitude and timing of recalled immunity after breakthrough infection is shaped by SARS-CoV-2 variants","volume":"55","author":"Koutsakos","year":"2022","journal-title":"Immunity"},{"key":"B10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41541-022-00546-1","article-title":"Moderate to severe SARS-CoV-2 infection primes vaccine-induced immunity more effectively than asymptomatic or mild infection","volume":"7","author":"Holder","year":"2022","journal-title":"NPJ Vaccines"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adk5845","article-title":"Enhanced SARS-CoV-2 humoral immunity following breakthrough infection builds upon the preexisting memory B cell pool","volume":"8","author":"Weber","year":"2023","journal-title":"Sci Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adg5301","article-title":"Durable reprogramming of neutralizing antibody responses following Omicron breakthrough infection","volume":"9","author":"Lee","year":"2023","journal-title":"Sci Adv"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101583","article-title":"SARS-CoV-2 breakthrough infections enhance T cell response magnitude, breadth, and epitope repertoire","volume":"5","author":"Tarke","year":"2024","journal-title":"Cell Rep Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104734","article-title":"Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study","volume":"95","author":"Altarawneh","year":"2023","journal-title":"EBioMedicine"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.126516","article-title":"Poor vaccine responders mask the true trend in vaccine effectiveness against progression to severe disease","volume":"43","author":"Dean","year":"2025","journal-title":"Vaccine"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12060564","article-title":"Declining levels of neutralizing antibodies to SARS-CoV-2 Omicron variants are enhanced by hybrid immunity and original\/Omicron bivalent vaccination","volume":"12","author":"Walmsley","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(22)00801-5","article-title":"Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression","volume":"23","author":"Bobrovitz","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"B18","volume-title":"TAG-VE statement on the meeting of 3 January on the COVID-19 situation in China","year":"2023"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2591504","article-title":"Immunogenicity of a recombinant subunit COVID-19 vaccine: a prospective, multi-centre, longitudinal study in Chinese Alzheimer's disease patients","volume":"21","author":"Weng","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00592-1","article-title":"Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape","volume":"21","author":"Tregoning","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials","volume":"22","author":"Zeng","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9070700","article-title":"Development of SARS-CoV-2 specific IgG and virus-neutralizing antibodies after infection with variants of concern or vaccination","volume":"9","author":"Neumann","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2023.06.022","article-title":"Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial","volume":"87","author":"Taucher","year":"2023","journal-title":"J Infect"},{"key":"B25","doi-asserted-by":"publisher","first-page":"4165","DOI":"10.1038\/s41467-022-31888-y","article-title":"Immune responses in Omicron SARS-CoV-2 breakthrough infection in vaccinated adults","volume":"13","author":"Kared","year":"2022","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-021-00590-x","article-title":"Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and variants of concern","volume":"32","author":"Ai","year":"2022","journal-title":"Cell Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41586-022-04980-y","article-title":"BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection","volume":"608","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.immuni.2021.07.008","article-title":"Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations","volume":"54","author":"Muecksch","year":"2021","journal-title":"Immunity"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0289713","article-title":"Correlation of a commercial platform's results with post-vaccination SARS-CoV-2 neutralizing antibody response and clinical host factors","volume":"18","author":"Slotkin","year":"2023","journal-title":"PloS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41421-023-00585-5","article-title":"Dosing interval regimen shapes potency and breadth of antibody repertoire after vaccination of SARS-CoV-2 RBD protein subunit vaccine","volume":"9","author":"Guo","year":"2023","journal-title":"Cell Discov"},{"key":"B31","doi-asserted-by":"publisher","first-page":"15831","DOI":"10.1038\/s41598-025-98627-3","article-title":"Temporal correlations between RBD-ACE2 blocking and binding antibodies to SARS-CoV-2 variants in CoronaVac-vaccinated individuals and their persistence in COVID-19 patients","volume":"15","author":"Poolchanuan","year":"2025","journal-title":"Sci Rep"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000898","article-title":"SARS-CoV-2 antibody responses are correlated to disease severity in COVID-19 convalescent individuals","volume":"206","author":"Hansen","year":"2021","journal-title":"J Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/v15112250","article-title":"Longitudinal analysis of antibody response following SARS-CoV-2 infection depending on disease severity: a prospective cohort study","volume":"15","author":"Zirou","year":"2023","journal-title":"Viruses"},{"key":"B34","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s43856-025-00828-4","article-title":"SARS-CoV-2 humoral immune responses in convalescent individuals over 12 months reveal severity-dependent antibody dynamics","volume":"5","author":"Siles Alvarado","year":"2025","journal-title":"Commun Med (Lond)"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101079","article-title":"Multi-omic longitudinal study reveals immune correlates of clinical course among hospitalized COVID-19 patients","volume":"4","author":"Diray-Arce","year":"2023","journal-title":"Cell Rep Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150107","article-title":"IL-13 is a driver of COVID-19 severity","volume":"6","author":"Donlan","year":"2021","journal-title":"JCI Insight"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3390\/v17111517","article-title":"Cytokine and antibody isotype responses in vaccinated healthcare workers with SARS-CoV-2 breakthrough infections","volume":"17","author":"Fern\u00e1ndez-Rojas","year":"2025","journal-title":"Viruses"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-5247(23)00171-4","article-title":"Dynamics of inflammatory responses after SARS-CoV-2 infection by vaccination status in the USA: a prospective cohort study","volume":"4","author":"Zhu","year":"2023","journal-title":"Lancet Microbe"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2025.110507","article-title":"Persistent IP-10\/CXCL10 dysregulation following mild Omicron breakthrough infection: immune network signatures across COVID-19 waves and implications for mRNA vaccine outcomes","volume":"278","author":"Vacharathit","year":"2025","journal-title":"Clin Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.cell.2022.01.011","article-title":"SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses","volume":"185","author":"Walls","year":"2022","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1506203","article-title":"Maternal-fetal cytokine profiles in acute SARS-CoV-2 \"breakthrough\" infection after COVID-19 vaccination","volume":"15","author":"Packer","year":"2024","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.cell.2020.08.001","article-title":"Severe COVID-19 is marked by a dysregulated myeloid cell compartment","volume":"182","author":"Schulte-Schrepping","year":"2020","journal-title":"Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc8511","article-title":"Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications","volume":"369","author":"Mathew","year":"2020","journal-title":"Science"},{"key":"B44","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/s41591-022-01715-4","article-title":"Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern","volume":"28","author":"Wratil","year":"2022","journal-title":"Nat Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114645","article-title":"Antigenic sin and multiple breakthrough infections drive converging evolution of COVID-19 neutralizing responses","volume":"43","author":"Paciello","year":"2024","journal-title":"Cell Rep"},{"key":"B46","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41421-025-00800-5","article-title":"Multiple infections with Omicron variants increase breadth and potency of Omicron-specific neutralizing antibodies","volume":"11","author":"You","year":"2025","journal-title":"Cell Discov"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1038\/s41467-024-45468-9","article-title":"Demographic and clinical factors associated with SARS-CoV-2 spike 1 antibody response among vaccinated US adults: the C4R study","volume":"15","author":"Kim","year":"2024","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10101601","article-title":"Determinants of antibody responses to SARS-CoV-2 vaccines: population-based longitudinal study (COVIDENCE UK)","volume":"10","author":"Jolliffe","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2020.04.001","article-title":"Improving vaccine-induced immunity: can baseline predict outcome","volume":"41","author":"Tsang","year":"2020","journal-title":"Trends Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1801564\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:17:48Z","timestamp":1774963068000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1801564\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,31]]},"references-count":49,"alternative-id":["10.3389\/fimmu.2026.1801564"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1801564","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,31]]},"article-number":"1801564"}}